Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419862 | 0.94 | DRD3 (0.41) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL5415343 | 0.89 | GPBAR1 (0.36) | KDM4EPOLBMAPTITGB3ITGA2B | |
| SCHEMBL5596886 | 0.88 | DRD3 (0.40) | KDM4EMEN1POLBMAPTKMT2A | |
| SCHEMBL5410473 | 0.87 | NOS3 (0.42) | MAPTNR1H4GPBAR1DRD3OPRL1 | |
| SCHEMBL5412551 | 0.85 | NR1H4 (0.39) | NR1H4GPBAR1DRD3 | |
| SCHEMBL5413655 | 0.85 | DRD2 (0.36) | GPBAR1OPRL1 | |
| SCHEMBL5428164 | 0.84 | MTNR1A (0.39) | — | |
| SCHEMBL5410104 | 0.83 | KDM1A (0.40) | KMT2AKDM1AGPBAR1 | |
| SCHEMBL5405065 | 0.83 | DRD2 (0.38) | GPBAR1DRD3 | |
| SCHEMBL5412545 | 0.83 | ITGB3 (0.41) | KDM4EMEN1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160894-B2 | Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-01-09 | — | — | US | claimed |
| EP-1632492-A1 | TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2006-03-08 | — | — | EP | claimed |
| US-20050096310-A1 | Tricyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-05-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096310-A1 | Tricyclic compound | MYLK3, CSNK1A1L, MYLK | KDM4E 3665/4885MEN1 3029/4885POLB 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.